These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 8707738)

  • 21. In vitro activity of piperacillin/tazobactam and other broad-spectrum antibiotics against bacteria from hospitalised patients in the British Isles.
    Livermore DM; Mushtaq S; James D; Potz N; Walker RA; Charlett A; Warburton F; Johnson AP; Warner M; Henwood CJ
    Int J Antimicrob Agents; 2003 Jul; 22(1):14-27. PubMed ID: 12842324
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers.
    Baron EJ; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):141-51. PubMed ID: 7648835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sensitivity pattern of gram negative bacilli to three beta-lactam/beta-lactamase inhibitor combinations using the automated API system.
    Anuradha K; Sailaja VV; Umabala P; Satheesh T; Lakshmi V
    Indian J Med Microbiol; 2007 Jul; 25(3):203-8. PubMed ID: 17901635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of piperacillin/tazobactam against 615 Pseudomonas aeruginosa strains isolated in intensive care units.
    Bonfiglio G; Laksai Y; Franceschini N; Perilli M; Segatore B; Bianchi C; Stefani S; Amicosante G; Nicoletti G
    Chemotherapy; 1998; 44(5):305-12. PubMed ID: 9732144
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.
    Lister PD
    Pharmacotherapy; 2000 Sep; 20(9 Pt 2):213S-218S; discussion 224S-228S. PubMed ID: 11001328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
    Liebowitz LD; Klugman KP
    S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1989; 12(6):495-510. PubMed ID: 2560422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Susceptibility survey of piperacillin alone and in the presence of tazobactam.
    Acar JF; Goldstein FW; Kitzis MD
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():23-8. PubMed ID: 8383653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An observational study on the epidemiology of respiratory tract bacterial pathogens and their susceptibility to four injectable beta-lactam antibiotics: piperacillin, piperacillin/tazobactam, ceftazidime and ceftriaxone.
    Varotto F; Maria GD; Azzaro R; Bellissima P; Amato R; Fogliani V; Muscianisi G; Vitale S; Girbino G; Andò F; Laganà P; Delia S; Jacoviello C; Maierna G; Pezza A; Covelli I; Magrì M; Napoletano G; Rossi A; Marone P; Sanguinetti C; Pela R; Tedeschi D; Viola B; Cicciarella S; Messina G; Rizza S; Fraschini F
    J Chemother; 2001 Aug; 13(4):413-23. PubMed ID: 11589485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).
    Eliopoulos GM; Klimm K; Ferraro MJ; Jacoby GA; Moellering RC
    Diagn Microbiol Infect Dis; 1989; 12(6):481-8. PubMed ID: 2560420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
    Perry CM; Markham A
    Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.
    Schoonover LL; Occhipinti DJ; Rodvold KA; Danziger LH
    Ann Pharmacother; 1995 May; 29(5):501-14. PubMed ID: 7655135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. A reevaluation after five years.
    Marshall SA; Aldridge KE; Allen SD; Fuchs PC; Gerlach EH; Jones RN
    Diagn Microbiol Infect Dis; 1995 Mar; 21(3):153-68. PubMed ID: 7648836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014.
    Sader HS; Castanheira M; Mendes RE; Flamm RK; Jones RN
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28137811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.